AtaiBeckley Relocates Headquarters to the United States

AtaiBeckley Completes U.S. Redomiciliation, Aiming for Enhanced Operational Efficiency

NEW YORK – December 31, 2025 – AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on developing novel mental health treatments, today announced the successful completion of its corporate redomiciliation. The parent entity has transitioned from its Netherlands incorporation to a U.S. corporation established in Delaware, effective after market close on December 30, 2025. This strategic move, overwhelmingly supported by shareholders with approximately 99% of votes cast in favor at a November 4, 2025 meeting, is poised to streamline operations and bolster alignment with its U.S. investor base.

The redomiciliation process involved an exchange of all outstanding ordinary shares of the former Netherlands entity for newly issued common stock of AtaiBeckley Inc. on a one-for-one basis. The company’s common stock will continue its trading on the Nasdaq Global Market under the familiar ticker symbol “ATAI.”

Management anticipates that this structural shift will yield significant benefits, including anticipated cost savings, a more simplified corporate framework, and improved alignment with its primary listing exchange and a substantial portion of its shareholder demographic. Furthermore, the company expects to realize more streamlined reporting processes and a reduction in overall administrative burdens, which could positively impact operational agility and investor relations.

This redomiciliation is a key component of AtaiBeckley’s ongoing corporate reorganization, following its strategic combination with Beckley Psytech Limited in November 2025. The company’s pipeline continues to advance, featuring promising drug candidates such as BPL-003 for treatment-resistant depression, VLS-01 for TRD, and EMP-01 for social anxiety disorder, all currently in Phase 2 clinical development. AtaiBeckley is also actively pursuing a drug discovery program focused on novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression. The overarching goal remains to deliver effective, scalable, and accessible psychiatric therapies that can be integrated into existing healthcare systems.

The strategic decision to redomicile to Delaware, a favored jurisdiction for U.S.-listed companies due to its well-established corporate law and governance framework, signals AtaiBeckley’s commitment to optimizing its operational and financial structure for long-term growth and U.S. market integration. Investors will be closely watching the realization of projected cost efficiencies and the impact on future capital management and reporting clarity. The existing S-3ASR shelf registration statement filed on September 29, 2025, provides a flexible mechanism for future registered resales, which complements the current corporate structure.

AtaiBeckley Inc. common stock traded at $3.98 prior to this announcement, comfortably positioned above its 200-day moving average of $3.42 and well off its 52-week low of $1.15, suggesting a degree of positive momentum preceding the news. The trading volume was consistent with its 20-day average, indicating a typical market response to the announcement.

For further details regarding the redomiciliation and other corporate actions, investors are directed to consult AtaiBeckley’s official filings with the U.S. Securities and Exchange Commission, accessible via the company’s Investor Relations website.

—

**About AtaiBeckley Inc.**

AtaiBeckley is a clinical-stage biopharmaceutical company dedicated to transforming patient outcomes by developing innovative, rapid-acting, and convenient treatments for mental health conditions. Formed through the strategic combination of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025, the company’s pipeline includes BPL-003 (mebufotenin benzoate nasal spray), VLS-01 (DMT buccal film), and EMP-01 ((R)-MDMA HCI) for various forms of depression and anxiety disorders, all in Phase 2 development. AtaiBeckley is also advancing a drug discovery program for novel 5-HT2AR agonists targeting opioid use disorder and treatment-resistant depression, aiming to introduce commercially scalable and integrated interventional psychiatry therapies.

—

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements regarding the anticipated benefits of the redomiciliation, the company’s business strategy, the potential success and timing of clinical trials, and future operational plans. Such statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. These risks include, but are not limited to, those detailed in the company’s filings with the Securities and Exchange Commission. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements.